BRIEF published on 04/15/2025 at 10:05, 8 months 4 days ago IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials Immune Response IOmx Therapeutics IOMX-0675 Clinical Trial Approval Solid Tumor Therapy
BRIEF published on 04/15/2025 at 10:05, 8 months 4 days ago IOmx Therapeutics obtient l'approbation pour les essais cliniques sur IOMX-0675 Réponse Immunitaire IOmx Therapeutics IOMX-0675 Approbation Des Essais Cliniques Thérapie Des Tumeurs Solides
PRESS RELEASE published on 04/15/2025 at 10:00, 8 months 4 days ago iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675 iOmx Therapeutics receives regulatory approval for clinical trial application of IOMX-0675, a LILRB1/LILRB2 dual-targeting antibody, to reverse immune suppression in solid tumors Regulatory Approval Clinical Trial Application IOmx Therapeutics IOMX-0675 Solid Tumor
BRIEF published on 12/19/2024 at 14:05, 1 year ago IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
BRIEF published on 12/19/2024 at 14:05, 1 year ago IOmx Therapeutics fait progresser IOMX-0675 avec une application d'essai clinique Traitement Du Cancer Thérapeutique IOmx IOMX-0675 Demande D'essai Clinique Récepteurs Immunosuppresseurs
PRESS RELEASE published on 12/19/2024 at 14:00, 1 year ago iOmx Therapeutics submits Clinical Trial Application for IOMX-0675 iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF published on 08/22/2024 at 10:05, 1 year 3 months ago IOmx Therapeutics Initiates Phase Ib with OMX-0407 Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 08/22/2024 at 10:05, 1 year 3 months ago IOmx Therapeutics lance la phase Ib avec OMX-0407 Essai Clinique Thérapie Contre Le Cancer OMX-0407 Phase Ib Thérapeutique IOmx
PRESS RELEASE published on 08/22/2024 at 10:00, 1 year 3 months ago iOmx Therapeutics Initiates Phase Ib with OMX-0407 iOmx Therapeutics initiates Phase Ib clinical trial with OMX-0407, showing favorable safety profile and anti-tumor activity in solid tumors. Expansion phase opens in kidney cancer and angiosarcoma Solid Tumors Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 06/27/2024 at 10:05, 1 year 5 months ago IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer Chief Financial Officer Biopharmaceutical Leadership IOmx Therapeutics Florian Schmid
Published on 12/19/2025 at 18:30, 1 hour 39 minutes ago Eagle Plains Shareholders Approve all Matters at Annual General Meeting
Published on 12/19/2025 at 14:40, 5 hours 29 minutes ago Northern Superior Announces Closing of the Arrangement
Published on 12/19/2025 at 13:30, 6 hours 39 minutes ago Quartz Commences Trading On The OTCQX Best Market Under The Symbol QZMRF
Published on 12/19/2025 at 13:30, 6 hours 39 minutes ago DataMetrex Announces Closing of Yuzu Payment Processing Solution Acquisition
Published on 12/19/2025 at 13:30, 6 hours 39 minutes ago Sterling Metals Provides Year End Update to Stakeholders
Published on 12/19/2025 at 19:56, 12 minutes ago Original-Research: European Lithium Limited (von First Berlin Equity Research GmbH): Buy
Published on 12/19/2025 at 19:00, 1 hour 8 minutes ago HIAG sells sites and properties as part of its sharpened corporate strategy and gains Swiss Post as a new tenant in Winterthur
Published on 12/19/2025 at 18:29, 1 hour 39 minutes ago clearvise AG commissions Triticum agri-photovoltaic project
Published on 12/19/2025 at 18:29, 1 hour 39 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 12/19/2025 at 08:30, 11 hours 39 minutes ago Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 08:30, 11 hours 39 minutes ago Réduction du capital par voie d’annulation d’actions propres
Published on 12/19/2025 at 07:00, 13 hours 9 minutes ago EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 13 hours 9 minutes ago EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION
Published on 12/18/2025 at 18:30, 1 day 1 hour ago Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
